Did you know RSV accounted for 11.4% of hospitalizations* for COPD? 1 Or that 80.4% of COPD patients¶ 60 years and above experienced an exacerbation during RSV-associated hospitalization?2 Learn more about RSV burden and prevention with GSK during the upcoming American Thoracic Society (ATS) International Conference in San Diego, CA.
GSK is pleased to invite you to join Navigating RSV in Adults: Insights into Disease and Vaccination, an RSV Learning Lounge, on Sunday, May 19, 2024, from 1:00-1:45 pm in Industry Theater 3.
In this session, you will hear from a panel of key experts and digital opinion leaders as they delve into the wide-ranging topic of Respiratory Syncytial Virus (RSV) in adults. Explore the true burden of RSV disease in adults, risk factors for severe disease in your patient population, and public health implications of RSV. The panel experts will also discuss innovative social and digital tactics to improve respiratory health literacy and considerations for RSV vaccine implementation in the adult population following the ACIP’s recommendation that adults aged ≥60 years may receive a single dose of an RSV vaccine using shared clinical decision-making.3
GSK works with top specialists to keep up with research and continue to navigate the RSV space.
For more information on RSV in adults, please visit the GSK Medical Booth #2219 and the GSK US Medical Affairs Portal.
We look forward to seeing you at the RSV Learning Lounge and during the ATS 2024 conference!
Sincerely,
GSK US Medical Affairs Team
Footnote: * in a prospective surveillance study among a subcohort of 1388 hospitalized adults (high-risk and aged ≥65 years) with chronic lung or heart disease ¶COPD/chronic bronchitis/emphysema
Reference:
- Falsey AR, et al. N Engl J Med. 2005;352(17):1749-1759.
- Tseng HF, et al. J Infect Dis. 2020;222(8):1298-1310.
- Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:793–801. http://dx.doi.org/10.15585/mmwr.mm7229a4.
PSE-US-2592